Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.
Feature|Articles|June 30, 2026
5 benign urology headlines you missed in Q2 2026
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
A roundup of the key stories on benign urologic conditions from the second quarter of 2026.
Advertisement
Advertisement
The second quarter of 2026 saw continued momentum across benign urology, with important regulatory developments, emerging clinical evidence, and advances in medical technology shaping the field. From proposed updates to testosterone replacement therapy labeling to the approval of the first oral carbapenem for complicated urinary tract infections, these headlines have the potential to influence clinical practice and future research.
Related to this article
A national survey found US hospitals expanded CAUTI prevention over 20 years, but use of key catheter-removal strategies remains variable.
The assay is designed to enable faster pathogen identification and susceptibility testing to guide UTI management.
Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
Advertisement
Advertisement